Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study

Daniel T Laskowitz, Ellen R Bennett, Rebecca J Durham, John J Volpi, Jonathan R Wiese, Michael Frankel, Elizabeth Shpall, Jeffry M Wilson, Jesse Troy, Joanne Kurtzberg, Daniel T Laskowitz, Ellen R Bennett, Rebecca J Durham, John J Volpi, Jonathan R Wiese, Michael Frankel, Elizabeth Shpall, Jeffry M Wilson, Jesse Troy, Joanne Kurtzberg

Abstract

Stroke is a major cause of death and long-term disability, affecting one in six people worldwide. The only currently available approved pharmacological treatment for ischemic stroke is tissue plasminogen activator; however, relatively few patients are eligible for this therapy. We hypothesized that intravenous (IV) infusion of banked unrelated allogeneic umbilical cord blood (UCB) would improve functional outcomes in patients with ischemic stroke. To investigate this, we conducted a phase I open-label trial to assess the safety and feasibility of a single IV infusion of non-human leukocyte antigen (HLA) matched, ABO matched, unrelated allogeneic UCB into adult stroke patients. Ten participants with acute middle cerebral artery ischemic stroke were enrolled. UCB units were matched for blood group antigens and race but not HLA, and infused 3-9 days post-stroke. The adverse event (AE) profile over a 12 month postinfusion period indicated that the treatment was well-tolerated in these stroke patients, with no serious AEs directly related to the study product. Study participants were also assessed using neurological and functional evaluations, including the modified Rankin Score (mRS) and National Institute of Health Stroke Scale (NIHSS). At 3 months post-treatment, all participants had improved by at least one grade in mRS (mean 2.8 ± 0.9) and by at least 4 points in NIHSS (mean 5.9 ± 1.4), relative to baseline. Together, these data suggest that a single i.v. dose of allogeneic non-HLA matched human UCB cells is safe in adults with ischemic stroke, and support the conduct of a randomized, placebo-controlled phase 2 study. Stem Cells Translational Medicine 2018;7:521-529.

Keywords: Cellular therapy; Clinical trials; Cord blood; Human cord blood; Stem cells; Umbilical cord; Umbilical cord blood.

© 2018 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Figures

Figure 1
Figure 1
Frequency of adverse events (AEs). AEs classified in terms of severity, seriousness, and relationship to the investigational treatment. A total of 113 AEs were reported; eight of these were also classified as serious adverse events. The only related AE was expected. Bars denote total reported AEs. The number of participants reporting an event is in parentheses. A summary of per participant AEs is included as Supporting Information.
Figure 2
Figure 2
Frequency of adverse events (AEs) according to CTCAE classification. Bars denote total reported AEs. The number of participants reporting an event is in parentheses.

References

    1. Mozaffarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics–2015 update: A report from the American Heart Association. Circulation 2015;131:e29–e322.
    1. Kalladka D, Muir KW. Brain repair: Cell therapy in stroke. Stem Cells Cloning 2014;7:31–44.
    1. Feigin VL, Forouzanfar MH, Krishnamurthi R et al. Global and regional burden of stroke during 1990–2010: Findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245–254.
    1. White BC, Sullivan JM, DeGracia DJ et al. Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. J Neurol Sci 2000;179:1–33.
    1. Hazell AS. Excitotoxic mechanisms in stroke: An update of concepts and treatment strategies. Neurochem Int 2007;50:941–953.
    1. Lo EH. A new penumbra: Transitioning from injury into repair after stroke. Nat Med 2008;14:497–500.
    1. Patel AR, Ritzel R, McCullough LD et al. Microglia and ischemic stroke: A double‐edged sword. Int J Physiol Pathophysiol Pharmacol 2013;5:73–90.
    1. Taylor RA, Sansing LH. Microglial responses after ischemic stroke and intracerebral hemorrhage. Clin Dev Immunol 2013;2013:1.
    1. Denes A, Vidyasagar R, Feng J et al. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab 2007;27:1941–1953.
    1. Prinz M, Priller J. Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease. Nat Rev Neurosci 2014;15:300–312.
    1. Hu X, Li P, Guo Y et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 2012;43:3063–3070.
    1. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
    1. Genentech USA. Full Prescribing Information: Activase (Alteplase) for Injection, for Intravenous Use. South San Francisco, CA: Genentech USA. Available at . Accessed April 17, 2018.
    1. Demaerschalk BM. Alteplase treatment in acute stroke: Incorporating food and drug administration prescribing information into existing acute stroke management guide. Curr Atheroscler Rep 2016;18:53.
    1. Berkhemer OA, Fransen PSS, Beumer D et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20.
    1. Campbell BCV, Mitchell PJ, Kleinig TJ et al. Endovascular therapy for ischemic stroke with perfusion‐imaging selection. N Engl J Med 2015;372:1009–1018.
    1. Goyal M, Demchuk AM, Menon BK et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019–1030.
    1. Jovin TG, Chamorro A, Cobo E et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296–2306.
    1. Saver JL, Goyal M, Bonafe A et al. Stent‐retriever thrombectomy after intravenous t‐PA vs. t‐PA alone in stroke. N Engl J Med 2015;372:2285–2295.
    1. Brown DA, Wijdicks EFM. Chapter 16 ‐ decompressive craniectomy in acute brain injury In: Wijdicks EFM, Kramer AH, eds. Handbook of Clinical Neurology. Vol 140 Amsterdam, The Netherlands: Elsevier, 2017:299–318.
    1. Taylor B, Lopresti M, Appelboom G et al. Hemicraniectomy for malignant middle cerebral artery territory infarction: An updated review. J Neurosurg Sci 2015;59:73–78.
    1. Stroke Unit Trialists’ Collaboration . Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2013. doi:10.1002/14651858.CD000197.pub3
    1. Veltkamp R, Gill D. Clinical trials of immunomodulation in ischemic stroke. Neurotherapeutics 2016;13:791–800.
    1. Kidwell CS, Liebeskind DS, Starkman S et al. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32:1349–1359.
    1. Chollet F, Cramer SC, Stinear C et al. Pharmacological therapies in post stroke recovery: Recommendations for future clinical trials. J Neurol 2014;261:1461–1468.
    1. Gervois P, Wolfs E, Ratajczak J et al. Stem cell‐based therapies for ischemic stroke: Preclinical results and the potential of imaging‐assisted evaluation of donor cell fate and mechanisms of brain regeneration. Med Res Rev 2016;36:1080–1126.
    1. Azad TD, Veeravagu A, Steinberg GK. Neurorestoration after stroke. Neurosurg Focus 2016;40:E2.
    1. Sun JM, Kurtzberg J. Cord blood for brain injury. Cytotherapy 2015;17:775–785.
    1. Dulamea AO. The potential use of mesenchymal stem cells in stroke therapy–from bench to bedside. J Neurol Sci 2015;352:1–11.
    1. Burns TC, Verfaillie CM, Low WC. Stem cells for ischemic brain injury: A critical review. J Comp Neurol 2009;515:125–144.
    1. Vendrame M, Cassady J, Newcomb J et al. Infusion of human umbilical cord blood cells in a rat model of stroke dose‐dependently rescues behavioral deficits and reduces infarct volume. Stroke 2004;35:2390–2395.
    1. Willing AE, Lixian J, Milliken M et al. Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. J Neurosci Res 2003;73:296–307.
    1. Nan Z, Grande A, Sanberg CD et al. Infusion of human umbilical cord blood ameliorates neurologic deficits in rats with hemorrhagic brain injury. Ann NY Acad Sci 2005;1049:84–96.
    1. Zhou H, Chang S, Rao M. Human cord blood applications in cell therapy: Looking back and look ahead. Expert Opin Biol Ther 2012;12:1059–1066.
    1. Chen N, Newcomb J, Garbuzova‐Davis S et al. Human umbilical cord blood cells have trophic effects on young and aging hippocampal neurons in vitro. Aging Dis 2010;1:173–190.
    1. Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol 2011;79:112–126.
    1. Jeong H, Yim HW, Cho YS et al. Efficacy and safety of stem cell therapies for patients with stroke: A systematic review and single arm meta‐analysis. Int J Stem Cells 2014;7:63–69.
    1. Steinberg GK, Kondziolka D, Wechsler LR et al. Clinical outcomes of transplanted modified bone marrow‐derived mesenchymal stem cells in stroke: A phase 1/2a study. Stroke 2016;47:1817–1824.
    1. Kalladka D, Sinden J, Pollock K et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): A phase I, first‐in‐man study. Lancet 2016;388:787–796.
    1. Quinn TJ, Lees KR, Hardemark HG et al. Initial experience of a digital training resource for modified Rankin scale assessment in clinical trials. Stroke 2007;38:2257–2261.
    1. Brott T, Adams HP Jr., Olinger CP et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke 1989;20:864–870.
    1. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: Implications for stroke clinical trials: A literature review and synthesis. Stroke 2007;38:1091–1096.
    1. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke 1988;19:1497–1500.
    1. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Md State Med J 1965;14:61–65.
    1. Kelly PJ, Furie KL, Shafqat S et al. Functional recovery following rehabilitation after hemorrhagic and ischemic stroke. Arch Phys Med Rehabil 2003;84:968–972.
    1. Kelly‐Hayes M, Wolf PA, Kase CS et al. Time course of functional recovery after stroke: The Framingham Study. J Neurol Rehabil 1989;3:65–70.
    1. Hankey GJ, Spiesser J, Hakimi Z et al. Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology 2007;68:1583–1587.
    1. Lai SM, Duncan PW. Stroke recovery profile and the Modified Rankin assessment. Neuroepidemiology 2001;20:26–30.
    1. Janowski M, Walczak P, Date I. Intravenous route of cell delivery for treatment of neurological disorders: A meta‐analysis of preclinical results. Stem Cells Dev 2010;19:5–16.
    1. George PM, Steinberg GK. Novel stroke therapeutics: Unraveling stroke pathophysiology and its impact on clinical treatments. Neuron 2015;87:297–309.
    1. Wei N, Yu SP, Gu X et al. Delayed intranasal delivery of hypoxic‐preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. Cell Transplant 2013;22:977–991.
    1. Reitz M, Demestre M, Sedlacik J et al. Intranasal delivery of neural stem/progenitor cells: A noninvasive passage to target intracerebral glioma. Stem Cells Translational Medicine 2012;1:866–873.
    1. Iihoshi S, Honmou O, Houkin K et al. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 2004;1007:1–9.
    1. Acosta SA, Tajiri N, Hoover J et al. Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke 2015;46:2616–2627.
    1. Yang WZ, Zhang Y, Wu F et al. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions. J Transl Med 2010;8:75.
    1. Banerjee S, Bentley P, Hamady M et al. Intra‐arterial immunoselected CD34+ stem cells for acute ischemic stroke. Stem Cells Translational Medicine 2014;3:1322.
    1. Moniche F, Gonzalez A, Gonzalez‐Marcos JR et al. Intra‐arterial bone marrow mononuclear cells in ischemic stroke: A pilot clinical trial. Stroke 2012;43:2242–2244.
    1. Savitz SI, Mattle HP. Advances in stroke: Emerging therapies. Stroke 2013;44:314–315.
    1. Vahidy FS, Alderman S, Savitz SI. Challenges enrolling patients with acute ischemic stroke into cell therapy trials. Stem Cells Dev 2013;22:27–30.
    1. Taguchi A, Sakai C, Soma T et al. Intravenous autologous bone marrow mononuclear cell transplantation for stroke: Phase1/2a clinical trial in a homogeneous group of stroke patients. Stem Cells Dev 2015;24:2207–2218.
    1. Borlongan CV. Bone marrow stem cell mobilization in stroke: A 'bonehead' may be good after all! Leukemia 2011;25:1674–1686.
    1. Prasad K, Sharma A, Garg A et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: A multicentric, randomized trial. Stroke 2014;45:3618–3624.
    1. Prasad K, Mohanty S, Bhatia R et al. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: A pilot study. Ind J Med Res 2012;136:221–228.
    1. Kondziolka D, Wechsler L, Goldstein S et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000;55:565–569.
    1. Kondziolka D, Steinberg GK, Wechsler L et al. Neurotransplantation for patients with subcortical motor stroke: A phase 2 randomized trial. J Neurosurg 2005;103:38–45.
    1. Mays R, Deans R. Adult adherent cell therapy for ischemic stroke: Clinical results and development experience using MultiStem. Transfusion 2016;56:6S–8S.
    1. Hess DC, Sila CA, Furlan AJ et al. A double‐blind placebo‐controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke 2014;9:381–386.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera